Calcium

United States Active Calcium Silicate Market to Grow With a Significant CAGR to 2026 - ResearchAndMarkets.com

Monday, July 26, 2021 - 5:18pm

The United States Active Calcium Silicate Market is projected to grow with a significant CAGR in the forecast period.

Key Points: 
  • The United States Active Calcium Silicate Market is projected to grow with a significant CAGR in the forecast period.
  • Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Active Calcium Silicate Market.
  • What is the market share of the leading vendors in the United States Active Calcium Silicate Market?
  • What modes and strategic moves are considered suitable for entering the United States Active Calcium Silicate Market?

Worldwide Active Calcium Silicate Industry to 2026 - Growing Preference for Advanced Ceramic Products Presents Opportunities - ResearchAndMarkets.com

Thursday, July 22, 2021 - 4:35pm

What are the inhibiting factors and impact of COVID-19 shaping the Global Active Calcium Silicate Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Active Calcium Silicate Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Active Calcium Silicate Market?
  • What is the competitive strategic window for opportunities in the Global Active Calcium Silicate Market?
  • What modes and strategic moves are considered suitable for entering the Global Active Calcium Silicate Market?

Calcium Propionate Market Report 2021 - Global Industry Size, Competition, Trends and Growth Opportunities to 2028 - ResearchAndMarkets.com

Friday, July 2, 2021 - 1:21pm

This study endeavors to evaluate different scenarios of COVID-19's impact on the future of the Calcium Propionate market from 2001 to 2028.

Key Points: 
  • This study endeavors to evaluate different scenarios of COVID-19's impact on the future of the Calcium Propionate market from 2001 to 2028.
  • Calcium Propionate Market Analysis by Types, Applications and Regions
    The research estimates global Calcium Propionate market revenues in 2021, considering the Calcium Propionate market prices, supply, demand, and trade analysis across regions.
  • The report covers North America, Europe, Asia-Pacific, Middle East, Africa, and LATAM Calcium Propionate market statistics from 2020 to 2028 with further division by leading product types, processes, and distribution channels of Calcium Propionate.
  • The status of the Calcium Propionate market in 16 key countries across the world is elaborated to enable an in-depth understanding of the Calcium Propionate industry.

Calcium electroporation delivered with EndoVE to treat advanced Oesophageal Cancer

Monday, June 28, 2021 - 5:00am

The trial aims to establish the safety and feasibility of treating patients with advanced oesophageal cancer in combination with local intratumoral injection of a calcium based solution.

Key Points: 
  • The trial aims to establish the safety and feasibility of treating patients with advanced oesophageal cancer in combination with local intratumoral injection of a calcium based solution.
  • Pulsed electrical fields generated by the ePORE and delivered directly to the tumour by the EndoVE endoscopic system results in electroporation of the cells and allows for passive diffusion of a locally injected calcium solution.
  • Compared to healthy cells, cancer cells are selectively less able to tolerate excessive intracellular calcium and results in their death.
  • Oesophageal cancer is the 7th most common cause of cancer morbidity and the 6th most common cause of cancer related death worldwide.

BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1

Tuesday, June 1, 2021 - 12:30pm

BridgeBio announced the Fast Track designation on World Hypoparathyroidism Awareness Day, an annual global awareness and education event designed to spotlight and support people living with ADH1 and other types of hypoparathyroidism.

Key Points: 
  • BridgeBio announced the Fast Track designation on World Hypoparathyroidism Awareness Day, an annual global awareness and education event designed to spotlight and support people living with ADH1 and other types of hypoparathyroidism.
  • Hypocalcemia can cause severe muscle cramping and seizures, while hypercalciuria can lead to impaired kidney function and kidney stone formation.
  • It is encouraging to receive Fast Track designation from the FDA as it recognizes the seriousness of ADH1 and the potential for encaleret to address this profound unmet medical need.
  • If the development program is successful, encaleret could be the first approved therapy indicated specifically for the treatment of ADH1.

Activation Products' Launches Perfect K2D3

Tuesday, May 25, 2021 - 9:09pm

b'TORONTO, May 20, 2021 /PRNewswire/ - Activation Products (CAN) Inc, one of North America\'s largest mid-sized manufacturers and developers of natural, certified organic, non-GMO, gluten-free and vegan products, is pleased to announce the launch of Perfect K2D3 offered in 15mL or 0.5 oz (17 drops).

Key Points: 
  • b'TORONTO, May 20, 2021 /PRNewswire/ - Activation Products (CAN) Inc, one of North America\'s largest mid-sized manufacturers and developers of natural, certified organic, non-GMO, gluten-free and vegan products, is pleased to announce the launch of Perfect K2D3 offered in 15mL or 0.5 oz (17 drops).
  • Perfect K2D3 is a first of its kind delivery solution thatsupports calcium metabolism, ensuring proper delivery of calcium throughout the body.\nThe D3 in Perfect K2D3 boosts \'calcium metabolism\' and absorption in your gut; regulating calcium, while the remaining supply is used to strengthen your immune system and maintain muscle strength.
  • said Ian Clark, CEO & Founder of Activation Products"Perfect K2D3 is a pure formulation, offering the proper placement of calcium to all the right places in the body and we are thrilled to add this to our line-up of products."
  • Its highly specialized seed pressing technology allows for all of its production and manufacturing to be of the highest, premium quality.

Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

Thursday, May 20, 2021 - 1:00pm

Treatment with EB612 resulted in a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin-adjusted calcium, and reduction of serum phosphate.

Key Points: 
  • Treatment with EB612 resulted in a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin-adjusted calcium, and reduction of serum phosphate.
  • Despite the challenges of COVID, I am grateful to the patients, investigators and team\xe2\x80\x99s focus to successfully executing the study.
  • Entera\xe2\x80\x99s operating loss was $2.4 million for the quarter ended March 31, 2021, compared to $2.9 million for the quarter ended March 31, 2020.\nResearch and development expenses were $1.2 million for the quarter ended March 31, 2021, compared to $1.6 million for the quarter ended March 31, 2020.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China

Friday, April 30, 2021 - 6:00am

The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.\nDr.

Key Points: 
  • The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.\nDr.
  • In 2020, Velphoro\xc2\xae became a global leader by value in the calcium-free phosphate binder market2.\n1 Zhang et al.
  • Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005950/en/\n'

Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021

Tuesday, March 23, 2021 - 11:05am

Importantly, we are presenting the first data on the treatment effect of TransCon PTH on the Hypoparathyroidism Patient Experience Scale (HPES).

Key Points: 
  • Importantly, we are presenting the first data on the treatment effect of TransCon PTH on the Hypoparathyroidism Patient Experience Scale (HPES).
  • Presentation title:TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension in 58 subjects.
  • TransCon PTH continues to be well-tolerated:
    No adverse events of hypocalcemia or hypercalcemia requiring visit to hospital, emergency room or urgent care.
  • In addition, to PaTH Forward, Ascendis Pharma is conducting the PaTHway Trial, a phase 3 clinical study evaluating the safety, tolerability and efficacy of TransCon PTH in adults with HP.

Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification

Thursday, March 4, 2021 - 12:41pm

Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.

Key Points: 
  • Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.
  • It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level.
  • Elastrins lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
  • The Elastrin team has developed a platform that can restore vascular health by removing pathological calcification specifically from sites where elastin has been degraded.